Thomas Gsponer
Overview
Explore the profile of Thomas Gsponer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
1019
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fluck M, Protte C, Giraud M, Gsponer T, Dossegger A
Genes (Basel)
. 2025 Jan;
15(12.
PMID: 39766802
Background: This study examines genetic variations in the systemic oxygen transport cascade during exhaustive exercise in physically trained tactical athletes. Research goal: To update the information on the distribution of...
2.
Keiser O, Blaser N, Davies M, Wessa P, Eley B, Moultrie H, et al.
Pediatr Infect Dis J
. 2015 Jul;
34(10):e254-9.
PMID: 26192393
Background: Combination antiretroviral therapy (ART) suppresses viral replication in HIV-infected children. The growth of virologically suppressed children on ART has not been well documented. We aimed to develop dynamic reference...
3.
Blaser N, Vizcaya L, Estill J, Zahnd C, Kalesan B, Egger M, et al.
J Stat Softw
. 2015 Jun;
64(10):1-22.
PMID: 26064082
Mathematical models of disease progression predict disease outcomes and are useful epidemiological tools for planners and evaluators of health interventions. The ???? package is a tool that simulates disease progression...
4.
Pilgrim T, Rothenbuhler M, Kalesan B, Pulver C, Stefanini G, Zanchin T, et al.
PLoS One
. 2014 Dec;
9(12):e114846.
PMID: 25489846
Introduction: Anemia and renal impairment are important co-morbidities among patients with coronary artery disease undergoing Percutaneous Coronary Intervention (PCI). Disease progression to eventual death can be understood as the combined...
5.
Avila D, Althoff K, Mugglin C, Wools-Kaloustian K, Koller M, Dabis F, et al.
J Acquir Immune Defic Syndr
. 2014 Jan;
65(1):e8-16.
PMID: 24419071
Objective: To describe the CD4 cell count at the start of combination antiretroviral therapy (cART) in low-income (LIC), lower middle-income (LMIC), upper middle-income (UMIC), and high-income (HIC) countries. Methods: Patients...
6.
Wandeler G, Gerber F, Rohr J, Chi B, Orrell C, Chimbetete C, et al.
Antivir Ther
. 2013 Dec;
19(5):521-5.
PMID: 24296645
Background: There is debate over using tenofovir or zidovudine alongside lamivudine in second-line antiretroviral therapy (ART) following stavudine failure. We analysed outcomes in cohorts from South Africa, Zambia and Zimbabwe...
7.
Schomaker M, Egger M, Ndirangu J, Phiri S, Moultrie H, Technau K, et al.
PLoS Med
. 2013 Nov;
10(11):e1001555.
PMID: 24260029
Background: There is limited evidence on the optimal timing of antiretroviral therapy (ART) initiation in children 2-5 y of age. We conducted a causal modelling analysis using the International Epidemiologic...
8.
Redmond S, von Elm E, Blumle A, Gengler M, Gsponer T, Egger M
J Clin Epidemiol
. 2013 Oct;
66(12):1367-75.
PMID: 24075598
Objectives: To identify factors associated with discrepant outcome reporting in randomized drug trials. Study Design And Setting: Cohort study of protocols submitted to a Swiss ethics committee 1988-1998: 227 protocols...
9.
Gsponer T, Gerber F, Bornkamp B, Ohlssen D, Vandemeulebroecke M, Schmidli H
Pharm Stat
. 2013 Sep;
13(1):71-80.
PMID: 24038922
Bayesian approaches to the monitoring of group sequential designs have two main advantages compared with classical group sequential designs: first, they facilitate implementation of interim success and futility criteria that...
10.
Wandeler G, Gsponer T, Bihl F, Bernasconi E, Cavassini M, Kovari H, et al.
J Infect Dis
. 2013 Aug;
208(9):1454-8.
PMID: 23901088
Hepatitis B virus (HBV) infection is a major cause of morbidity and mortality in human immunodeficiency virus (HIV)-infected patients worldwide. It is unclear whether HIV-related outcomes are affected by HBV...